How much does Neratinib affect the kidneys?

Neratinib (Neratinib) has been associated with hepatotoxicity, characterized by increased liver enzymes. In the experiment, 10% of patients had an increase in alanine aminotransferase (ALT) ≥2×ULN, 5% of patients had an increase in aspartate aminotransferase (AST) ≥2×ULN, and 1.7% of patients had an increase in AST or ALT >5×ULN (≥Grade 3). Hepatotoxicity or elevated hepatic transaminases resulted in discontinuation of neratinib in 1.7% of patients treated with neratinib. Total bilirubin, AST, ALT, and alkaline phosphatase should be measured monthly for 3 months before starting treatment with neratinib and then every 3 months as clinically indicated during treatment. These tests should also be performed in patients who develop grade 3 diarrhea or any signs or symptoms of hepatotoxicity, such as worsening fatigue, nausea, vomiting, right upper quadrant tenderness, pyrexia, rash, or eosinophilia.